Tibet Rhodiola Pharmaceutical Holding Balance Sheet Health
Financial Health criteria checks 5/6
Tibet Rhodiola Pharmaceutical Holding has a total shareholder equity of CN¥3.7B and total debt of CN¥761.5M, which brings its debt-to-equity ratio to 20.6%. Its total assets and total liabilities are CN¥5.1B and CN¥1.4B respectively. Tibet Rhodiola Pharmaceutical Holding's EBIT is CN¥1.0B making its interest coverage ratio -12.8. It has cash and short-term investments of CN¥3.1B.
Key information
20.6%
Debt to equity ratio
CN¥761.55m
Debt
Interest coverage ratio | -12.8x |
Cash | CN¥3.08b |
Equity | CN¥3.69b |
Total liabilities | CN¥1.40b |
Total assets | CN¥5.09b |
Recent financial health updates
Recent updates
Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Seems To Use Debt Rather Sparingly
May 21Shareholders Will Be Pleased With The Quality of Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Earnings
May 03Under The Bonnet, Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Returns Look Impressive
Mar 22Financial Position Analysis
Short Term Liabilities: 600211's short term assets (CN¥3.9B) exceed its short term liabilities (CN¥1.4B).
Long Term Liabilities: 600211's short term assets (CN¥3.9B) exceed its long term liabilities (CN¥30.3M).
Debt to Equity History and Analysis
Debt Level: 600211 has more cash than its total debt.
Reducing Debt: 600211's debt to equity ratio has increased from 0% to 20.6% over the past 5 years.
Debt Coverage: 600211's debt is well covered by operating cash flow (146.5%).
Interest Coverage: 600211 earns more interest than it pays, so coverage of interest payments is not a concern.